The cost of taking ribociclib for one year in China

Ribociclib, sold under the brand name Kisqali, is a drug used to treat certain breast cancers. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals.

Ribociclib is available as an oral tablet. The recommended dose of ribociclib is 600 mg (three 200 mg film-coated tablets) taken orally once daily for 21 days followed by 7 days off for a complete 28-day cycle. Ribociclib can be taken with food or alone. Ribociclib was coadministered with letrozole 2.5 mg once daily in 28-day cycles.

The market price of ribociclib in China is approximately 8,000 yuan per box. Typically, one box of ribociclib is enough for one month. Therefore, without counting medical insurance reimbursement, the annual cost is approximately 96,000 yuan (8,000 yuan x 12 months). However, it is worth noting that ribociclib has been included in China's national medical insurance directory, and eligible patients can reimburse part of the drug cost through medical insurance, which will reduce the actual burden on patients.

Ribociclib is available in EuropeThe price of 200mg*21 tablets is about 22,000 yuan. This price is significantly higher than the domestic market price, which may be due to factors such as import costs, taxes, and pricing strategies in different regions.

The price of the original research version of ribociclib available in India is about 3,000 yuan per box. This relatively low price may be due to the low cost of drug production in India or the fierce market competition. However, it is important to note that despite the lower price, patients still need to ensure the quality and reliability of the source of the medicine when purchasing.

To sum up, the domestic cost of taking Ribociclib for one year is approximately 96,000 yuan without considering medical insurance reimbursement. However, actual costs may vary depending on factors such as the patient's health insurance status, where the drug was purchased, and when the drug was purchased. Therefore, when purchasing drugs, patients should fully understand the relevant information and make reasonable choices based on their actual situation.